Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MNPR-101-PCTA-Ac225
- Development stage
- Preclinical
- Lead developer
- Monopar Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MNPR-101-PCTA-Ac225 is a **radiotherapeutic agent** comprising Monopar’s proprietary humanized monoclonal antibody MNPR-101, which targets the **urokinase plasminogen activator receptor (uPAR)**, conjugated with the radioisotope **actinium-225** (Ac-225) via the metal binding chelator **PCTA**. This **radio-immunotherapeutic** seeks to selectively deliver potent alpha radiation to uPAR-expressing tumor cells, aiming for high specificity with minimal off-target toxicity. The compound is being developed primarily for advanced cancers with high uPAR expression, but potential indications extend to severe COVID-19 and other diseases characterized by aberrant uPAR activity. Preclinical studies have demonstrated 98% radiochemical purity and high stability of the conjugate. The drug is being co-developed by **Monopar Therapeutics** and **NorthStar Medical Radioisotopes**[1][7][8].
- Brand names
- MNPR-101-PCTA-Ac225MNPR101-PCTA-Ac225MNPR 101-PCTA-Ac225
- Other names
- MNPR-101-Ac225MNPR101-Ac225MNPR 101-Ac225MNPR101-PCTA-Ac225MNPR-101-PCTA-Ac225MNPR 101-PCTA-Ac225
02
Targets
PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on MNPR-101-PCTA-Ac225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MNPR-101-PCTA-Ac225.